Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.

Mirella SalvatoreJennifer M LaplanteRosemary SoaveNina OrfaliMarkus PlateKoen van BesienKirsten St George

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2020)

Our data suggest that baloxavir treatment can be effective in treating neuraminidase inhibitor-resistant influenza in profoundly immunocompromised patients. Randomized clinical trials are needed to define the role of baloxavir alone and combined with oseltamivir for the treatment of influenza in SCT recipients and other immunocompromised populations.

Keyphrases

hematopoietic stem cell
end stage renal disease
bone marrow
stem cell transplantation
combination therapy
big data
peritoneal dialysis
artificial intelligence
patient reported outcomes
kidney transplantation